Celgene Corporation (CELG) : Ghost Tree Capital added new position in Celgene Corporation during the most recent quarter end. The investment management firm now holds 90,202 shares of Celgene Corporation which is valued at $9 Million , the company said in a statement filed on May 13, 2016 with the SEC.Celgene Corporation makes up approximately 7.28% of Ghost Tree Capital’s portfolio.
Other Hedge Funds, Including , Salem Investment Counselors Inc reduced its stake in CELG by selling 570 shares or 6.78% in the most recent quarter. The Hedge Fund company now holds 7,838 shares of CELG which is valued at $785,054. Celgene Corporation makes up approx 0.10% of Salem Investment Counselors Inc’s portfolio.Cannell Peter B Co Inc reduced its stake in CELG by selling 88,188 shares or 4.52% in the most recent quarter. The Hedge Fund company now holds 1,864,346 shares of CELG which is valued at $186.7 Million. Celgene Corporation makes up approx 6.75% of Cannell Peter B Co Inc’s portfolio.Bridgewater Wealth Financial Management boosted its stake in CELG in the latest quarter, The investment management firm added 539 additional shares and now holds a total of 2,753 shares of Celgene Corporation which is valued at $275,740. Celgene Corporation makes up approx 0.10% of Bridgewater Wealth Financial Management’s portfolio.Retirement Systems Of Alabama boosted its stake in CELG in the latest quarter, The investment management firm added 126,629 additional shares and now holds a total of 668,049 shares of Celgene Corporation which is valued at $69.1 Million. Celgene Corporation makes up approx 0.41% of Retirement Systems Of Alabama’s portfolio.Hgk Asset Management Inc boosted its stake in CELG in the latest quarter, The investment management firm added 89 additional shares and now holds a total of 4,240 shares of Celgene Corporation which is valued at $438,458. Celgene Corporation makes up approx 0.04% of Hgk Asset Management Inc’s portfolio.
Celgene Corporation opened for trading at $104.24 and hit $105.87 on the upside on Wednesday, eventually ending the session at $105.11, with a gain of 1.36% or 1.41 points. The heightened volatility saw the trading volume jump to 36,57,006 shares. Company has a market cap of $81,418 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.